ODM-201: A new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Karim Fizazi, Laurence Albiges, Yohann Loriot, Christophe Massard

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    64 Citations (Scopus)

    Résumé

    Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.

    langue originaleAnglais
    Pages (de - à)1007-1017
    Nombre de pages11
    journalExpert Review of Anticancer Therapy
    Volume15
    Numéro de publication9
    Les DOIs
    étatPublié - 2 sept. 2015

    Contient cette citation